Spots Global Cancer Trial Database for blastic phase chronic myelogenous leukemia
Every month we try and update this database with for blastic phase chronic myelogenous leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey | NCT03647215 | Chronic Phase C... Accelerated Pha... Blastic Phase C... Philadelphia Ch... | 18 Years - | Incyte Corporation | ||
| FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | NCT00053963 | Blastic Phase C... Childhood Centr... Childhood Choro... Childhood Chron... Childhood Crani... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Spina... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro... Relapsing Chron... Unspecified Chi... | romidepsin | - 21 Years | National Cancer Institute (NCI) | |
| Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia | NCT00003735 | Leukemia | topotecan hydro... | - 21 Years | Children's Oncology Group | |
| Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers | NCT00015951 | Leukemia Myelodysplastic... | bevacizumab cytarabine mitoxantrone hy... | 18 Years - 120 Years | University of Maryland, Baltimore | |
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | NCT00003619 | Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni... | filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo... | 19 Years - 90 Years | National Cancer Institute (NCI) | |
| Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | NCT00101231 | Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... Recurrent Adult... Recurrent Adult... Relapsing Chron... | alvocidib | 1 Year - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia | NCT00002588 | Leukemia | etoposide topotecan hydro... | 18 Years - | Case Comprehensive Cancer Center | |
| Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia | NCT00466726 | Leukemia | bcr-abl p210-b3... sargramostim | 18 Years - 120 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia | NCT00003230 | Leukemia | paclitaxel | 18 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia | NCT01159301 | Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... Recurrent Adult... Unspecified Adu... | entinostat sorafenib tosyl... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | NCT00070538 | Leukemia Myelodysplastic... | cytarabine laromustine | 18 Years - | National Cancer Institute (NCI) | |
| Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia | NCT00244829 | Leukemia | imatinib mesyla... adjuvant therap... | - | Fred Hutchinson Cancer Center | |
| Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome | NCT00002800 | Leukemia Myelodysplastic... Neutropenia | filgrastim lintuzumab cytarabine etoposide idarubicin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | NCT00006213 | Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... | BMS-214662 pharmacological... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia | NCT00003997 | Leukemia Myelodysplastic... | irofulven | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy in Treating Patients Who Have Hematologic Cancer | NCT00004047 | Leukemia Myelodysplastic... | exatecan mesyla... | - | Daiichi Sankyo | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia | NCT00278330 | Blastic Phase C... Recurrent Adult... Recurrent Adult... Refractory Anem... Relapsing Chron... Untreated Adult... Untreated Adult... | alvocidib vorinostat | 18 Years - | National Cancer Institute (NCI) | |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | NCT00087204 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | becatecarin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia | NCT00002693 | Leukemia Neutropenia | filgrastim carboplatin topotecan hydro... | 18 Years - | Mayo Clinic | |
| VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | NCT00070538 | Leukemia Myelodysplastic... | cytarabine laromustine | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia | NCT00466726 | Leukemia | bcr-abl p210-b3... sargramostim | 18 Years - 120 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center | |
| Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | NCT01849276 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... Recurrent Adult... Untreated Adult... | metformin hydro... cytarabine laboratory biom... | 18 Years - | Northwestern University | |
| Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer | NCT00290641 | Chronic Myelopr... Leukemia Lymphoma Myelodysplastic... | filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | NCT01564277 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Contiguous Stag... de Novo Myelody... Noncontiguous S... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Adult... Stage I Adult B... Stage III Adult... Stage IV Adult ... Untreated Adult... Untreated Adult... | rasburicase allopurinol | 18 Years - | Roswell Park Cancer Institute | |
| Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases | NCT00450983 | Graft Versus Ho... Leukemia Myelodysplastic... | muromonab-CD3 natural killer ... fludarabine pho... methotrexate thiotepa gene expression... flow cytometry immunologic tec... allogeneic hema... in vitro-treate... total-body irra... | - 45 Years | Fred Hutchinson Cancer Center | |
| Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer | NCT00064285 | Leukemia | alvocidib imatinib mesyla... | 18 Years - | Virginia Commonwealth University | |
| Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia | NCT00618696 | Leukemia Myelodysplastic... | anti-CD45 monoc... yttrium Y 90 an... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia | NCT00275080 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Secondary Acute... Splenic Margina... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Untreated Adult... Untreated Adult... | vorinostat decitabine | 18 Years - | National Cancer Institute (NCI) | |
| BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | NCT00006213 | Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... | BMS-214662 pharmacological... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia | NCT00006092 | Leukemia | Arsenic Trioxid... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Tipifarnib in Treating Patients With Advanced Hematologic Cancer | NCT00005967 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia | NCT00002831 | Leukemia | Filgrastim Busulfan Cyclophosphamid... Cyclosporine Decitabine (DAC... Methotrexate Methylprednisol... Tacrolimus Allogeneic Bone... Peripheral Bloo... | 15 Years - 55 Years | M.D. Anderson Cancer Center | |
| Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia | NCT00244829 | Leukemia | imatinib mesyla... adjuvant therap... | - | Fred Hutchinson Cancer Center | |
| Natural History Study of Patients With Chronic Myelogenous Leukemia | NCT00429910 | Leukemia | 18 Years - 120 Years | Dana-Farber Cancer Institute | ||
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma | NCT00003079 | Leukemia Lymphoma | bryostatin 1 cytarabine | 18 Years - | Virginia Commonwealth University | |
| Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia | NCT00054431 | Accelerated Pha... Blastic Phase C... Childhood Chron... Chronic Myeloge... Relapsing Chron... | imatinib mesyla... decitabine laboratory biom... | - | National Cancer Institute (NCI) | |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | NCT00087204 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | becatecarin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00101088 | Accelerated Pha... Blastic Phase C... Chronic Myeloge... Chronic Phase C... Relapsing Chron... | imatinib mesyla... temsirolimus laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy | NCT00006220 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | arsenic trioxid... tretinoin | 15 Years - | Washington University School of Medicine | |
| Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias | NCT00098436 | Leukemia | laromustine temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00053144 | Leukemia | cytarabine irinotecan hydr... | 15 Years - | Roswell Park Cancer Institute | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer | NCT00534430 | Leukemia Myelodysplastic... | busulfan cyclosporine etoposide mycophenolate m... allogeneic bone... allogeneic hema... peripheral bloo... total-body irra... | 16 Years - 50 Years | City of Hope Medical Center | |
| Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer | NCT00295880 | Myeloproliferat... Leukemia Lymphoma Myelodysplastic... | umbilical cord ... | 12 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia | NCT00002598 | Leukemia | recombinant int... sargramostim cyclophosphamid... cytarabine etoposide methotrexate mitoxantrone hy... bone marrow abl... radiation thera... | 16 Years - | Memorial Sloan Kettering Cancer Center | |
| Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | NCT00052598 | Accelerated Pha... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Childhood Chron... Childhood Myelo... Recurrent Adult... Recurrent Child... Relapsing Chron... Secondary Acute... | therapeutic all... aldesleukin laboratory biom... flow cytometry | - | Fred Hutchinson Cancer Center | |
| Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias | NCT00098436 | Leukemia | laromustine temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia | NCT00066326 | Leukemia | imatinib mesyla... tanespimycin | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer | NCT00012376 | Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... Chronic Phase C... Paroxysmal Noct... Previously Trea... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Thrombocytopeni... Untreated Adult... | bryostatin 1 sargramostim laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML | NCT00003407 | Drug/Agent Toxi... Leukemia Myelodysplastic... Neutropenia | amifostine trih... cytarabine mitoxantrone hy... | 18 Years - 120 Years | Rush University Medical Center | |
| Tipifarnib in Treating Young Patients With Refractory Leukemia | NCT00022451 | Leukemia | tipifarnib | - 21 Years | National Institutes of Health Clinical Center (CC) | |
| STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia | NCT00015834 | Blastic Phase C... Chronic Myeloge... Relapsing Chron... | imatinib mesyla... cytarabine | 18 Years - | National Cancer Institute (NCI) | |
| Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center | |
| Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant | NCT00526292 | Leukemia Myelodysplastic... | natural killer ... cyclophosphamid... fludarabine | - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00053144 | Leukemia | cytarabine irinotecan hydr... | 15 Years - | Roswell Park Cancer Institute | |
| Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia | NCT00006092 | Leukemia | Arsenic Trioxid... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer | NCT00064285 | Leukemia | alvocidib imatinib mesyla... | 18 Years - | Virginia Commonwealth University | |
| Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia | NCT00023920 | Blastic Phase C... Chronic Myeloge... | bevacizumab idarubicin cytarabine | 18 Years - | National Cancer Institute (NCI) | |
| Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia | NCT00345826 | Leukemia | dasatinib | 18 Years - | Jonsson Comprehensive Cancer Center | |
| SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes | NCT00098826 | Acute Undiffere... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... Untreated Adult... | ispinesib laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer | NCT00004132 | Drug/Agent Toxi... Leukemia Lymphoma Multiple Myelom... Oral Complicati... Radiation Toxic... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide quality-of-life... radiation thera... | 12 Years - 65 Years | National Cancer Institute (NCI) | |
| Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome | NCT00005593 | Leukemia Myelodysplastic... | carboplatin fludarabine pho... topotecan hydro... | 12 Years - | Case Comprehensive Cancer Center | |
| Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma | NCT00002766 | Leukemia Lymphoma | dactinomycin sargramostim carmustine cyclophosphamid... cytarabine daunorubicin hy... doxorubicin hyd... etoposide mercaptopurine methotrexate mitoxantrone hy... pegaspargase prednisone vincristine sul... radiation thera... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia | NCT00816283 | Leukemia | dasatinib vorinostat cytogenetic ana... gene expression... mutation analys... reverse transcr... flow cytometry laboratory biom... | 18 Years - | City of Hope Medical Center | |
| Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia | NCT00012259 | Leukemia | troxacitabine | 16 Years - 120 Years | Takeda | |
| High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies | NCT00002818 | Drug/Agent Toxi... Leukemia Lymphoma Multiple Myelom... | cytarabine deoxycytidine | 18 Years - 120 Years | Virginia Commonwealth University | |
| Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00002890 | Leukemia Myelodysplastic... | lintuzumab | 16 Years - | Memorial Sloan Kettering Cancer Center | |
| STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis | NCT00006475 | Leukemia | imatinib mesyla... | 18 Years - | Novartis | |
| Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer | NCT00004065 | Bladder Cancer Breast Cancer Colorectal Canc... Gastric Cancer Head and Neck C... Kidney Cancer Leukemia Lung Cancer Melanoma (Skin) Ovarian Cancer Prostate Cancer Unspecified Adu... | tanespimycin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | NCT00003693 | Leukemia Myelodysplastic... | Dolastatin 10 | - | M.D. Anderson Cancer Center | |
| Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | NCT00309842 | Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Myelofibrosis MDS Refractory Anem... Chronic Lymphoc... Prolymphocytic ... Non-Hodgkin's L... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | filgrastim cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... total-body irra... | - 55 Years | Masonic Cancer Center, University of Minnesota | |
| FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | NCT00053963 | Blastic Phase C... Childhood Centr... Childhood Choro... Childhood Chron... Childhood Crani... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Spina... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro... Relapsing Chron... Unspecified Chi... | romidepsin | - 21 Years | National Cancer Institute (NCI) | |
| Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | NCT00098423 | Accelerated Pha... Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | tanespimycin cytarabine | 18 Years - | National Cancer Institute (NCI) | |
| Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia | NCT00083070 | Leukemia | temozolomide | 1 Year - 21 Years | Children's Oncology Group | |
| Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia | NCT00003735 | Leukemia | topotecan hydro... | - 21 Years | Children's Oncology Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
